Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

Abstract

Imatinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML). The drug shows great efficacy in chronic phase, but is less effective in maintaining hematologic remissions in blast crisis patients. Our group has previously described several cell… (More)
DOI: 10.1038/sj.leu.2402775

Topics

8 Figures and Tables